Canadian trial tests engineered immune cells to fight tough cancers
NCT ID NCT07297667
Summary
This early-stage study is testing a new type of personalized immune cell therapy called GCAR1 in people with advanced cancers that have stopped responding to standard treatments. The main goal is to find the safest and most effective dose of GCAR1 for patients with specific types of sarcoma, kidney cancer, and breast cancer. Researchers will also monitor how the treatment affects the cancer and track any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
Contact Phone: •••-•••-••••
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
Contact Phone: •••-•••-••••
-
University Health Network Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.